2 documents found, page 1 of 1
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an i...
Gurnari, Carmelo; Robin, Marie; Adès, Lionel; Aljurf, Mahmoud; Almeida, António M.; Duarte, Fernando Barroso; Bernard, Elsa; Cutler, CoreyFor patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis. Biologic-assignment clinical trials have indicated that in eligible patients, allo-HCT is associated with superior clinical outcomes co...
Immune-monitoring of myelodysplastic neoplasms: recommendations from the i4MDS ...
i4MDS consortium; Tentori, Cristina A.; Zhao, Lin P.; Tinterri, Benedetta; Strange, Kathryn E.; Zoldan, Katharina; Dimopoulos, KonstantinosAdvancements in comprehending myelodysplastic neoplasms (MDS) have unfolded significantly in recent years, elucidating a myriad of cellular and molecular underpinnings integral to disease progression. While molecular inclusions into prognostic models have substantively advanced risk stratification, recent revelations have emphasized the pivotal role of immune dysregulation within the bone marrow milieu during M...